Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching

Pigment Cell and Melanoma Research

Volumn 24, Issue 4, 2011, Pages 631-642

  Eichhoff, Ossia M ^a   Weeraratna, Ashani ^b   Zipser, Marie C ^a   Denat, Laurence ^c   Widmer, Daniel S ^a   Xu, Mai ^b   Kriegl, Lydia ^d   Kirchner, Thomas ^d   Larue, Lionel ^c   Dummer, Reinhard ^a   Hoek, Keith S ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b WISTAR INSTITUTE   (United States)

^c Centre National de la Recherche Scientifique   (France)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

LEF1; Melanoma; MITF; TCF4; WNT5A

Indexed keywords

BETA CATENIN; LYMPHOID ENHANCER FACTOR 1; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR TCF4; UNCLASSIFIED DRUG; WNT PROTEIN; WNT5A PROTEIN;

ARTICLE; CANCER GROWTH; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GENE SWITCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MELANOMA CELL; PHENOTYPE; PROTEIN EXPRESSION;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MELANOMA; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PHENOTYPE; SKIN NEOPLASMS; TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 80051875971     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00871.x     Document Type: Article

References (63)

1. Adams, C.L., Chen, Y.T., Smith, S.J., and Nelson, W.J. (1998). Mechanisms of epithelial cell-cell adhesion and cell compaction revealed by high-resolution tracking of E-cadherin-green fluorescent protein. J. Cell Biol. 142, 1105-1119.
2. Alexaki, V.I., Javelaud, D., Van Kempen, L.C. et al. (2010). GLI2-mediated melanoma invasion and metastasis. J. Natl Cancer Inst. 102, 1148-1159.
3. Arce, L., Yokoyama, N.N., and Waterman, M.L. (2006). Diversity of LEF/TCF action in development and disease. Oncogene 25, 7492-7504.
4. Arce, L., Pate, K.T., and Waterman, M.L. (2009). Groucho binds two conserved regions of LEF-1 for HDAC-dependent repression. BMC Cancer 9, 159.
5. Bachmann, I.M., Straume, O., Puntervoll, H.E., Kalvenes, M.B., and Akslen, L.A. (2005). Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin. Cancer Res. 11, 8606-8614.
6. Bennett, D.C. (2008). How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21, 27-38.
7. Bittner, M., Meltzer, P., Chen, Y. et al. (2000). Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540.
8. Brantjes, H., Barker, N., Van Es, J., and Clevers, H. (2002). TCF: lady Justice casting the final verdict on the outcome of Wnt signalling. Biol. Chem. 383, 255-261.
9. Busam, K.J., Iversen, K., Coplan, K.C., and Jungbluth, A.A. (2001). Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am. J. Surg. Pathol. 25, 197-204.
10. Carreira, S., Goodall, J., Aksan, I., La Rocca, S.A., Galibert, M.D., Denat, L., Larue, L., and Goding, C.R. (2005). Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433, 764-769.
11. Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, L., and Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20, 3426-3439.
12. Chien, A.J., Moore, E.C., Lonsdorf, A.S., Kulikauskas, R.M., Rothberg, B.G., Berger, A.J., Major, M.B., Hwang, S.T., Rimm, D.L., and Moon, R.T. (2009). Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl. Acad. Sci. USA 106, 1193-1198.
13. Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127, 469-480.
14. Clifford, R.L., Deacon, K., and Knox, A.J. (2008). Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, AND GSK3(beta). J. Biol. Chem. 283, 35337-35353.
15. Da Forno, P.D., Pringle, J.H., Hutchinson, P., Osborn, J., Huang, Q., Potter, L., Hancox, R.A., Fletcher, A., and Saldanha, G.S. (2008). WNT5A expression increases during melanoma progression and correlates with outcome. Clin. Cancer Res. 14, 5825-5832.
16. Davis, J.M. (2001). Basic Cell Culture: A Practical Approach. (Oxford: Oxford University Press).
17. Delmas, V., Beermann, F., Martinozzi, S. et al. (2007). Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 21, 2923-2935.
18. Demunter, A., Libbrecht, L., Degreef, H., De Wolf-Peeters, C., and Van Den Oord, J.J. (2002). Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Mod. Pathol. 15, 454-461.
19. Dissanayake, S.K., Wade, M., Johnson, C.E. et al. (2007). The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J. Biol. Chem. 282, 17259-17271.
20. Dissanayake, S.K., Olkhanud, P.B., O'connell, M.P. et al. (2008). Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res. 68, 10205-10214.
21. Dorsky, R.I., Moon, R.T., and Raible, D.W. (1998). Control of neural crest cell fate by the Wnt signalling pathway. Nature 396, 370-373.
22. Eichhoff, O.M., Zipser, M.C., Xu, M., Weeraratna, A.T., Mihic, D., Dummer, R., and Hoek, K.S. (2010). The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report. Melanoma Res. 20, 349-355.
23. Geertsen, R.C., Hofbauer, G.F., Yue, F.Y., Manolio, S., Burg, G., and Dummer, R. (1998). Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions. J. Invest. Dermatol. 111, 497-502.
24. Goodall, J., Martinozzi, S., Dexter, T.J., Champeval, D., Carreira, S., Larue, L., and Goding, C.R. (2004). Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. Mol. Cell. Biol. 24, 2915-2922.
25. Haughian, J.M., Reno, E.M., Thorne, A.M., and Bradford, A.P. (2009). Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis. Int. J. Cancer 125, 2556-2564.
26. Hecht, A., and Stemmler, M.P. (2003). Identification of a promoter-specific transcriptional activation domain at the C terminus of the Wnt effector protein T-cell factor 4. J. Biol. Chem. 278, 3776-3785.
27. Herzig, M., Savarese, F., Novatchkova, M., Semb, H., and Christofori, G. (2007). Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling. Oncogene 26, 2290-2298.
28. Hoek, K.S., and Goding, C.R. (2010). Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 23, 746-759.
29. Hoek, K.S., Schlegel, N.C., Brafford, P. et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19, 290-302.
30. Hoek, K.S., Eichhoff, O.M., Schlegel, N.C., Dobbeling, U., Kobert, N., Schaerer, L., Hemmi, S., and Dummer, R. (2008a). In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68, 650-656.
31. Hoek, K.S., Schlegel, N.C., Eichhoff, O.M. et al. (2008b). Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res. 21, 665-676.
32. Hur, E.M., and Zhou, F.Q. (2010). SK3 signalling in neural development. Nat. Rev. Neurosci. 11, 539-551.
33. Jeffs, A.R., Glover, A.C., Slobbe, L.J. et al. (2009). A gene expression signature of invasive potential in metastatic melanoma cells. PLoS ONE 4, e8461.
34. Katoh, M. (2009). Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int. J. Mol. Med. 23, 763-769.
35. Klarmann, G.J., Decker, A., and Farrar, W.L. (2008). Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 3, 59-63.
36. Klaus, A., and Birchmeier, W. (2008). Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 8, 387-398.
37. Korinek, V., Barker, N., Morin, P.J., Van Wichen, D., De Weger, R., Kinzler, K.W., Vogelstein, B., and Clevers, H. (1997). Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275, 1784-1787.
38. Kriegl, L., Horst, D., Reiche, J.A., Engel, J., Kirchner, T., and Jung, A. (2010). LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer. J. Transl. Med. 8, 123.
39. Kuphal, S., Poser, I., Jobin, C., Hellerbrand, C., and Bosserhoff, A.K. (2004). Loss of E-cadherin leads to upregulation of NFkappaB activity in malignant melanoma. Oncogene 23, 8509-8519.
40. Larue, L., and Delmas, V. (2006). The WNT/Beta-catenin pathway in melanoma. Front. Biosci. 11, 733-742.
41. Larue, L., Kumasaka, M., and Goding, C.R. (2003). Beta-catenin in the melanocyte lineage. Pigment Cell Res. 16, 312-317.
42. Levy, C., Khaled, M., and Fisher, D.E. (2006). MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12, 406-414.
43. Loercher, A.E., Tank, E.M., Delston, R.B., and Harbour, J.W. (2005). MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 168, 35-40.
44. Ma, C., Wang, J., Gao, Y., Gao, T.W., Chen, G., Bower, K.A., Odetallah, M., Ding, M., Ke, Z., and Luo, J. (2007). The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res. 67, 7756-7764.
45. Mikesch, J.H., Steffen, B., Berdel, W.E., Serve, H., and Muller-Tidow, C. (2007). The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia 21, 1638-1647.
46. Nelson, W.J., and Nusse, R. (2004). Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303, 1483-1487.
47. Novak, A., and Dedhar, S. (1999). Signaling through beta-catenin and Lef/Tcf. Cell. Mol. Life Sci. 56, 523-537.
48. O'connell, M.P., Fiori, J.L., Baugher, K.M. et al. (2009). Wnt5A activates the calpain-mediated cleavage of filamin A. J. Invest. Dermatol. 129, 1782-1789.
49. Reifenberger, J., Knobbe, C.B., Wolter, M., Blaschke, B., Schulte, K.W., Pietsch, T., Ruzicka, T., and Reifenberger, G. (2002). Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int. J. Cancer 100, 549-556.
50. Rimm, D.L., Caca, K., Hu, G., Harrison, F.B., and Fearon, E.R. (1999). Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol. 154, 325-329.
51. Robinson, D.R., Zylstra, C.R., and Williams, B.O. (2008). Wnt signaling and prostate cancer. Curr. Drug Targets 9, 571-580.
52. Schepsky, A., Bruser, K., Gunnarsson, G.J., Goodall, J., Hallsson, J.H., Goding, C.R., Steingrimsson, E., and Hecht, A. (2006). The microphthalmia-associated transcription factor Mitf interacts with beta-catenin to determine target gene expression. Mol. Cell. Biol. 26, 8914-8927.
53. Segditsas, S., and Tomlinson, I. (2006). Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25, 7531-7537.
54. Shin, S.Y., Yoon, S.C., Kim, Y.H., Kim, Y.S., and Lee, Y.H. (2002). Phosphorylation of glycogen synthase kinase-3beta at serine-9 by phospholipase Cgamma1 through protein kinase C in rat 3Y1 fibroblasts. Exp. Mol. Med. 34, 444-450.
55. Smith, A.P., Hoek, K., and Becker, D. (2005). Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol. Ther. 4, 1018-1029.
56. Steingrimsson, E., Copeland, N.G., and Jenkins, N.A. (2004). Melanocytes and the microphthalmia transcription factor network. Annu. Rev. Genet. 38, 365-411.
57. Takeda, K., Yasumoto, K., Takada, R., Takada, S., Watanabe, K., Udono, T., Saito, H., Takahashi, K., and Shibahara, S. (2000). Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J. Biol. Chem. 275, 14013-14016.
58. Takigawa, Y., and Brown, A.M. (2008). Wnt signaling in liver cancer. Curr. Drug Targets 9, 1013-1024.
59. Vance, K.W., and Goding, C.R. (2004). The transcription network regulating melanocyte development and melanoma. Pigment Cell Res. 17, 318-325.
60. Weeraratna, A.T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., and Trent, J.M. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288.
61. Widlund, H.R., Horstmann, M.A., Price, E.R., Cui, J., Lessnick, S.L., Wu, M., He, X., and Fisher, D.E. (2002). {beta}-Catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J. Cell Biol. 158, 1079-1087.
62. Yasumoto, K., Takeda, K., Saito, H., Watanabe, K., Takahashi, K., and Shibahara, S. (2002). Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling. EMBO J. 21, 2703-2714.
63. Zipser, M.C., Eichhoff, O.M., Widmer, D.S. et al. (2011). A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell Melanoma Res. 24, 326-333.